BLK vs DMAC · P/E 27, rev $24.22B vs $157.4M cap
BlackRock Inc (BLK) versus DiaMedica Therapeutics Inc (DMAC) — a side-by-side from cached financials, not a winner call.
BlackRock Inc (BLK) is a asset management company listed on NYSE. It is led by Larry Fink.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Latest reported BLK revenue for 2025-12-31 was $24.22B. Net income was $5.55B. Revenue was up 89.3% from 2024-12-31 to 2025-12-31. BLK currently screens at market cap $172.19B and trailing P/E 26.6.
DMAC does not have a complete income-statement cache yet.
BLK currently screens at market cap $172.19B and trailing P/E 26.6. DMAC currently screens at market cap $157.4M.
Not investment advice. Open the BLK and DMAC stock pages for the full models.
Not investment advice.